Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of palbociclib plus endocrine therapy as a forth line and beyond in patients with hormone receptor-positive HER2-negative advanced breast cancer: A retrospective study

Trial Profile

Safety and efficacy of palbociclib plus endocrine therapy as a forth line and beyond in patients with hormone receptor-positive HER2-negative advanced breast cancer: A retrospective study

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Dec 2018

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 13 Jun 2018 New trial record
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top